Shopping Cart
- Remove All
- Your shopping cart is currently empty
Prexasertib is a potent and selective Chk1/Chk2 inhibitor. Prexasertib increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Treatment of cells with LY2606368 results in the rapid appearance of TUNEL and pH2AX-positive double-stranded DNA breaks in the S-phase cell population.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.444 € | 1-2 weeks | |
50 mg | 1.881 € | 1-2 weeks | |
100 mg | 2.375 € | 1-2 weeks |
Description | Prexasertib is a potent and selective Chk1/Chk2 inhibitor. Prexasertib increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. LY2606368 causes replication catastrophe and antitumor effects through CHK1-d |
Targets&IC50 | Chk2:8 nM (IC50), Chk1:<1 nM (IC50), Chk1:0.9 nM (Ki) |
Alias | LY-2606368, LY2606368, LY 2606368 |
Molecular Weight | 461.49 |
Formula | C19H23N7O5S |
Cas No. | 1234015-55-4 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.